Physician profile
Shakil Khan
NPI 1043343122
$3,906.83
in general payments reported to CMS, 2019-2025
34 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $309 · 2021: $988 · 2022: $989 · 2023: $329 · 2024: $404 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $585.82 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $552.62 | 2019-2023 | |
| Amgen INC. | $512.98 | 2019-2023 | Repatha |
| Pfizer INC. | $319.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $248.52 | 2020-2023 | Farxiga |
| Novo Nordisk INC | $163.10 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $143.58 | 2019-2021 | |
| Boston Scientific Corporation | $132.73 | 2021-2025 | Watchman Access System, Watchman Flx |
| Kestra Medical Technology Services, INC. | $124.80 | 2022 | |
| Esperion Therapeutics, INC. | $109.43 | 2020-2021 | |
| Biosense Webster, INC. | $100.99 | 2024 | Carto 3 |
| Lundbeck LLC | $99.77 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $86.76 | 2019-2023 | Camzyos |
| Astellas Pharma US INC | $81.48 | 2019-2021 | |
| Abbott Laboratories | $72.97 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $64.72 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $51.72 | 2023-2025 | Onpattro |
| Sanofi-Aventis U.S. LLC | $44.49 | 2019-2021 | |
| Abiomed | $36.94 | 2024-2025 | Impella |
| Cvrx, INC. | $34.84 | 2024 | Barostim Neo System |
| Atricure, INC. | $31.56 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $31.48 | 2019 | |
| Merck Sharp & Dohme LLC | $30.12 | 2021-2022 | |
| Lantheus Medical Imaging, INC. | $29.97 | 2020-2022 | |
| Gilead Sciences, INC. | $28.07 | 2019 | |
| Impulse Dynamics (USA) INC. | $25.26 | 2024 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $24.00 | 2024 | Opsumit, Uptravi |
| Cardiva Medical, INC. | $23.97 | 2021 | |
| Heartflow, INC. | $23.29 | 2025 | |
| Vifor Pharma, INC. | $20.26 | 2019 | |
| Smith+Nephew, INC. | $19.50 | 2023 | Pico, Renasys Go V2 Home |
| Allergan, INC. | $19.35 | 2019 | |
| Medicomp INC | $19.24 | 2024 | Telepatch Cardiac Monitor |
| Kowa Pharmaceuticals America, INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shakil Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.